210 related articles for article (PubMed ID: 20001169)
41. The use of generic drugs in prevention of chronic disease is far more cost-effective than thought, and may save money.
Shrank WH; Choudhry NK; Liberman JN; Brennan TA
Health Aff (Millwood); 2011 Jul; 30(7):1351-7. PubMed ID: 21734210
[TBL] [Abstract][Full Text] [Related]
42. Patterns and predictors of generic narrow therapeutic index drug use among older adults.
Gagne JJ; Polinski JM; Kesselheim AS; Choudhry NK; Hutchins D; Matlin OS; Tong A; Shrank WH
J Am Geriatr Soc; 2013 Sep; 61(9):1586-91. PubMed ID: 24001285
[TBL] [Abstract][Full Text] [Related]
43. Pricing of drugs with heterogeneous health insurance coverage.
Ferrara I; Missios P
J Health Econ; 2012 Mar; 31(2):440-56. PubMed ID: 22484368
[TBL] [Abstract][Full Text] [Related]
44. Impact of substitution among generic drugs on persistence and adherence: A retrospective claims data study from 2 Local Healthcare Units in the Lombardy Region of Italy.
Colombo GL; Agabiti-Rosei E; Margonato A; Mencacci C; Montecucco CM; Trevisan R; Catapano AL
Atheroscler Suppl; 2016 Jun; 21():1-8. PubMed ID: 26948872
[TBL] [Abstract][Full Text] [Related]
45. Generic substitution of anti-epileptic drugs. A needed battle?
Al-Baradie RS
Neurosciences (Riyadh); 2008 Jul; 13(3):211-6. PubMed ID: 21063327
[TBL] [Abstract][Full Text] [Related]
46. [Comparison of compliance and cost effectiveness between brand-name statins and generic statins].
He L; Du X; Wang WH; Ma CS
Zhonghua Liu Xing Bing Xue Za Zhi; 2020 Nov; 41(11):1900-1904. PubMed ID: 33297658
[No Abstract] [Full Text] [Related]
47. Generic utilization and cost-sharing for prescription drugs.
Gibson TB; McLaughlin CG; Smith DG
Adv Health Econ Health Serv Res; 2010; 22():195-219. PubMed ID: 20575234
[TBL] [Abstract][Full Text] [Related]
48. Free statins disrupt pharmacy benefit plans.
Reinke T
Manag Care; 2012 Nov; 21(11):19-20. PubMed ID: 23236713
[No Abstract] [Full Text] [Related]
49. Brand name versus generic drugs: the ethical quandary in caring for our sophisticated patients while trying to reduce health-care costs: facts and controversies.
Payette M; Grant-Kels JM
Clin Dermatol; 2013; 31(6):772-6. PubMed ID: 24160285
[TBL] [Abstract][Full Text] [Related]
50. Citizens' preferences for brand name drugs for treating acute and chronic conditions: a pilot study.
Denoth A; Pinget C; Wasserfallen JB
Appl Health Econ Health Policy; 2011 Mar; 9(2):81-7. PubMed ID: 21332252
[TBL] [Abstract][Full Text] [Related]
51. Cisplatin-induced hyponatremia in malignancy: comparison between brand-name and generic formulation.
Ochi N; Yamane H; Hotta K; Fujii H; Isozaki H; Honda Y; Yamagishi T; Kubo T; Tanimoto M; Kiura K; Takigawa N
Drug Des Devel Ther; 2014; 8():2401-8. PubMed ID: 25584019
[TBL] [Abstract][Full Text] [Related]
52. Copayment reductions generate greater medication adherence in targeted patients.
Maciejewski ML; Farley JF; Parker J; Wansink D
Health Aff (Millwood); 2010 Nov; 29(11):2002-8. PubMed ID: 21041739
[TBL] [Abstract][Full Text] [Related]
53. Economic grand rounds: experience with mandated use of generic medications for patients covered by the mental health safety net.
Amirsadri A; Chapman T; Breen M; Drake W; Arfken CL
Psychiatr Serv; 2014 Jul; 65(7):850-2. PubMed ID: 26037001
[TBL] [Abstract][Full Text] [Related]
54. When is a brand a generic? In a contract with a PBM.
Cahn LJ
Manag Care; 2010 Sep; 19(9):21-5. PubMed ID: 20931886
[No Abstract] [Full Text] [Related]
55. Adherence to changing from brand-name to generic atorvastatin in newly treated patients: a retrospective cohort study using health insurance claims.
Mano Y; Fukushima S; Kuroda H; Ohshima H; Kato Y; Ohuchi K; Maezawa K; Momose Y; Ikeda S; Asahi M
J Pharm Health Care Sci; 2015; 1():12. PubMed ID: 26819723
[TBL] [Abstract][Full Text] [Related]
56. [Treatment persistence with brand-name vs. generic metformin in monotherapy for type 2 diabetes: real-life retrospective study using the propensity matching score].
Sicras-Mainar A; Sicras-Navarro A
Semergen; 2021; 47(5):321-331. PubMed ID: 34049795
[TBL] [Abstract][Full Text] [Related]
57. Healthy User Bias in Comparative Safety Studies for Brand-Name vs. Generic Products: The Example of Warfarin.
Bird ST; Flowers N; Zhao Y; McKean S; Izem R; Wernecke M; Kozlowski S; MaCurdy TE; Kelman JA; Graham DJ
Clin Pharmacol Ther; 2019 Nov; 106(5):1037-1045. PubMed ID: 31062343
[TBL] [Abstract][Full Text] [Related]
58. Comparative effectiveness and costs of generic and brand-name gabapentin and venlafaxine in patients with neuropathic pain or generalized anxiety disorder in Spain.
Sicras-Mainar A; Rejas-Gutiérrez J; Navarro-Artieda R
Clinicoecon Outcomes Res; 2015; 7():299-312. PubMed ID: 26082655
[TBL] [Abstract][Full Text] [Related]
59. The non-medical switching of prescription medications.
Dolinar R; Kohn CG; Lavernia F; Nguyen E
Postgrad Med; 2019 Jun; 131(5):335-341. PubMed ID: 31081414
[TBL] [Abstract][Full Text] [Related]
60. Medication adherence and use of generic drug therapies.
Briesacher BA; Andrade SE; Fouayzi H; Chan KA
Am J Manag Care; 2009 Jul; 15(7):450-6. PubMed ID: 19589012
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
